کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
5701364 1601568 2017 6 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Cost-effectiveness analysis of the use of comprehensive molecular profiling before initiating monoclonal antibody therapy against metastatic colorectal cancer in Japan
ترجمه فارسی عنوان
تجزیه و تحلیل هزینه-اثربخشی استفاده از پروفایل های مولکولی جامع قبل از شروع درمان آنتی بادی منوکلونال در برابر سرطان متاستاتیک کولورکتال در ژاپن
کلمات کلیدی
موضوعات مرتبط
علوم پزشکی و سلامت پزشکی و دندانپزشکی تومور شناسی
چکیده انگلیسی


- Comprehensive molecular profiling can be used to detect several mutations.
- The comprehensive screening of metastatic colorectal cancer is a cost-effective approach.
- Cost-effective price of comprehensive screening depends on the cost of panitumumab.

IntroductionComprehensive molecular profiling has become a pivotal component of precision medicine involving anti-epidermal growth factor receptor (EGFR) monoclonal antibody therapy for metastatic colorectal cancer. The objective of this study was to determine the cost-effectiveness of comprehensive molecular profiling before initiating anti-EGFR therapies for metastatic colorectal cancer.MethodsA Markov model simulating the health outcomes and total costs was developed to estimate the life years and quality-adjusted life years (QALYs) gained by metastatic colorectal cancer patients treated with anti-EGFR drug. The cost-effectiveness of comprehensive screening versus RAS mutation screening was evaluated over a 5-year period using the incremental cost-effectiveness ratio (ICER). The ICER per additional QALY gained was calculated, and sensitivity analyses were performed to evaluate the robustness of the assumptions across a range of values. Analyses were made from the perspective of the Japanese healthcare payer.ResultsComprehensive screening before monoclonal antibody therapy provided 0.063 additional QALYs (0.075 life years) at the cost of 268,274 Japanese Yen (JPY). The ICER was 4,260,187 JPY/QALY compared to RAS screening. The median progression-free survival obtained by sensitivity analyses for the subgroup not responding to anti-EGFR therapy showed that comprehensive screening and panitumumab prices had the strongest influence on cost-effectiveness.ConclusionThe incremental cost per QALY gained indicated that comprehensive screening was more cost-effective compared to RAS screening. With a willingness-to-pay value of 6 million JPY/QALY, comprehensive screening can be considered for the genetic testing of patients before providing monoclonal antibody therapy.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Journal of Cancer Policy - Volume 12, June 2017, Pages 61-66
نویسندگان
, , , , , ,